Organisation paid for research Program year 2022 Source: CMS Open Payments

New Jersey Urology

Neither a doctor nor a teaching hospital

Research payments

$330,779

38 payments

Through program year 2022, New Jersey Urology is reported as receiving $330,779 in research payments, across 38 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2022	Research	$66,268	6
2021	Research	$226,332	19
2020	Research	$34,900	8
2019	Research	$3,279	5

Breakdown

Who paid Research payments · program years 2019–2022

Palette Life Sciences, Inc. $227,200 8 payments
Medtronic USA, Inc. $33,139 7 payments
Urotronic, Inc $25,168 2 payments
Bayer HealthCare Pharmaceuticals Inc. $25,150 8 payments
Medtronic, Inc. $10,562 4 payments
Allergan Inc. $5,040 6 payments
Urovant Sciences Inc $4,520 3 payments

Studies the money was for Research payments · program years 2019–2022

Randomized Trial of Barrigel $227,200 8 payments
BASIC Study $30,910 4 payments
BAY 1841788 AR/Antagonist Prostate CA Phase lll (ARAMIS) $25,150 8 payments
Robust III $23,972 1 payment
Titan 1 $10,562 4 payments
A Study Evaluating the Efficacy and Safety of BOTOX Intravesical Instillation in Patients with Overactive Bladder and Urinary Incontinence $5,040 6 payments
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence $4,500 2 payments
Amplitude $2,229 3 payments
Stream $1,196 1 payment
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) $20 1 payment

What the money was spent on Research payments · program years 2019–2022

Patient care $25,168 2 payments
Overhead $25,168 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.